Zoetis earns license for Cytopoint skin therapyJanuary 4, 2017Veterinary drug maker Zoetis Inc. in December received a U.S. Department of Agriculture license for Cytopoint, which the Parsippany, N.J., company described as the first monoclonal antibody (mAb) therapy approved “to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs.”
Education Center - SponsoredVector-Borne Disease Coming to a Neighborhood Near You: Which Tests to Reach For, and Why?by • AntechWhether it’s a screening to identify exposure to tick-borne pathogens, or a broad molecular diagnostic panel to help with acute disease detection or confirm the presence of genetic material, these options empower veterinary teams, guide treatment, and support antimicrobial stewardship.
